<DOC>
	<DOC>NCT00807846</DOC>
	<brief_summary>This Is A Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis</brief_summary>
	<brief_title>A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Polyarticular (both rheumatoid factor positive and rheumatoid factor negative),oligoarticular and extended oligoarticular JIA for ≥3 months meeting the International League of Associations for Rheumatology (ILAR) criteria for Juvenile Idiopathic Arthritis (JIA) Subjects with Systemic JIA with active arthritis in at least 1 joint but without active systemic features are eligible ≥2 years of age and &lt;18 years of age prior to the Baseline visit Body weight ≥10 kg at the Baseline visit Candidate for chronic NSAID therapy in the Investigator's judgment Psoriatic arthritis, enthesitisrelated arthritis, and undifferentiated arthritis types of JIA Active systemic features over the prior 12 weeks in children with systemic Juvenile Idiopathic Arthritis (JIA) Subjects with psoriatic arthritis, enthesitisrelated arthritis, and undifferentiated arthritis should be excluded Subjects with active Systemic JIA should not be enrolled</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Juvenile Arthritis; Juvenile Rheumatoid Arthritis;Blood Pressure;Juvenile Idiopathic Arthritis</keyword>
</DOC>